Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Reaches New 12-Month High - What's Next?

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR reached a new 52-week high of $9.23, trading at $8.95, with a volume of 658 shares.
• The company reported $0.16 EPS for the last quarter, exceeding analysts' expectations of $0.14, but its revenue of $672.90 million fell short of the anticipated $719.55 million.
• Shionogi has a market capitalization of $15.07 billion and a low debt-to-equity ratio of 0.01, indicating a strong financial position.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $9.23 and last traded at $8.95, with a volume of 658 shares changing hands. The stock had previously closed at $8.95.

Shionogi & Co., Ltd. Unsponsored ADR Trading Up 1.9%

The company's 50-day moving average price is $8.73 and its 200-day moving average price is $8.33. The firm has a market cap of $15.50 billion, a price-to-earnings ratio of 15.24, a price-to-earnings-growth ratio of 2.02 and a beta of 0.20. The company has a quick ratio of 6.13, a current ratio of 6.63 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.02. The company had revenue of $672.90 million during the quarter, compared to analyst estimates of $719.55 million. Equities analysts expect that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.